Table 4 Proportion of patients achieving ≥ 0.5-point reductions in ACQ-5 score, by baseline characteristics

ITT population

 Patients with ≥ 0.5-point reduction in ACQ-5 score, n (%)

272/465 (58)

201/462 (44)

 Odds ratio (mepolizumab/placebo), 95% CI; p-value

1.91 (1.45, 2.52); p < 0.001

Age at asthma onset: < 18 years

 Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%)

78/132 (59)

50/119 (42)

 Odds ratio (mepolizumab/placebo), 95% CI

1.84 (1.06, 3.20)

Age at asthma onset: 18–< 40 years

 Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%)

93/172 (54)

69/171 (40)

 Odds ratio (mepolizumab/placebo), 95% CI

1.93 (1.20, 3.12)

Age at asthma onset: ≥ 40 years

 Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%)

100/160 (63)

82/172 (48)

 Odds ratio (mepolizumab/placebo), 95% CI

2.27 (1.39, 3.70)

Lung function: ≤ 60% predicted FEV₁

 Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%)

149/243 (61)

95/238 (40)

 Odds ratio (mepolizumab/placebo), 95% CI

2.53 (1.73, 3.71)

Lung function: > 60–80% predicted FEV₁

 Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%)

101/176 (57)

86/177 (49)

 Odds ratio (mepolizumab/placebo), 95% CI

1.40 (0.87, 2.24)

Lung function: ≥ 80% predicted FEV₁

 Patients with ≥ 0.5-point reduction in ACQ-5 score, n/N (%)

22/46 (48)

20/47 (43)

 Odds ratio (mepolizumab/placebo), 95% CI

1.45 (0.47, 4.48)